Cargando…

Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI

Mucopolysaccharidosis (MPS) is a rare genetic disease involving active storage of glycosaminoglycans (GAGs). Accumulation of GAGs in the connective tissues of airways leads to progressive pulmonary dysfunction. Studies conducted in Taiwan revealed mainly restrictive pulmonary dysfunction, whereas th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tulebayeva, Assel, Sharipova, Maira, Boranbayeva, Riza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168931/
https://www.ncbi.nlm.nih.gov/pubmed/31991612
http://dx.doi.org/10.3390/diagnostics10020063
_version_ 1783523745310179328
author Tulebayeva, Assel
Sharipova, Maira
Boranbayeva, Riza
author_facet Tulebayeva, Assel
Sharipova, Maira
Boranbayeva, Riza
author_sort Tulebayeva, Assel
collection PubMed
description Mucopolysaccharidosis (MPS) is a rare genetic disease involving active storage of glycosaminoglycans (GAGs). Accumulation of GAGs in the connective tissues of airways leads to progressive pulmonary dysfunction. Studies conducted in Taiwan revealed mainly restrictive pulmonary dysfunction, whereas the same studies in Egypt and California revealed obstructive pulmonary dysfunction. The contradictory results and lack of studies of respiratory system in patients with MPS in Asian populations are an indication to study pulmonary impairment in patients with MPS in Kazakhstan. The prospective study of respiratory system in patients with MPS was conducted in the Scientific Centre of Paediatrics and Paediatric Surgery. Patients with MPS (n = 11) were examined for respiratory function. Different types of pulmonary dysfunction were present in MPS patients, they were mainly of a restrictive pathology. One patient with MPS II had obstructive dysfunction. Enzyme replacement therapy was provided for an average duration of four years, leading to improvements in respiratory function in two patients with total normalization in one. All observed patients had respiratory dysfunction, mainly of the restrictive type. Pulmonary impairment in patients with MPS is the main reason for death. Thus, it is necessary to follow up with pulmonary function assessments in children with MPS.
format Online
Article
Text
id pubmed-7168931
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71689312020-04-20 Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI Tulebayeva, Assel Sharipova, Maira Boranbayeva, Riza Diagnostics (Basel) Article Mucopolysaccharidosis (MPS) is a rare genetic disease involving active storage of glycosaminoglycans (GAGs). Accumulation of GAGs in the connective tissues of airways leads to progressive pulmonary dysfunction. Studies conducted in Taiwan revealed mainly restrictive pulmonary dysfunction, whereas the same studies in Egypt and California revealed obstructive pulmonary dysfunction. The contradictory results and lack of studies of respiratory system in patients with MPS in Asian populations are an indication to study pulmonary impairment in patients with MPS in Kazakhstan. The prospective study of respiratory system in patients with MPS was conducted in the Scientific Centre of Paediatrics and Paediatric Surgery. Patients with MPS (n = 11) were examined for respiratory function. Different types of pulmonary dysfunction were present in MPS patients, they were mainly of a restrictive pathology. One patient with MPS II had obstructive dysfunction. Enzyme replacement therapy was provided for an average duration of four years, leading to improvements in respiratory function in two patients with total normalization in one. All observed patients had respiratory dysfunction, mainly of the restrictive type. Pulmonary impairment in patients with MPS is the main reason for death. Thus, it is necessary to follow up with pulmonary function assessments in children with MPS. MDPI 2020-01-24 /pmc/articles/PMC7168931/ /pubmed/31991612 http://dx.doi.org/10.3390/diagnostics10020063 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tulebayeva, Assel
Sharipova, Maira
Boranbayeva, Riza
Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
title Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
title_full Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
title_fullStr Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
title_full_unstemmed Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
title_short Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
title_sort respiratory dysfunction in children and adolescents with mucopolysaccharidosis types i, ii, iva, and vi
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168931/
https://www.ncbi.nlm.nih.gov/pubmed/31991612
http://dx.doi.org/10.3390/diagnostics10020063
work_keys_str_mv AT tulebayevaassel respiratorydysfunctioninchildrenandadolescentswithmucopolysaccharidosistypesiiiivaandvi
AT sharipovamaira respiratorydysfunctioninchildrenandadolescentswithmucopolysaccharidosistypesiiiivaandvi
AT boranbayevariza respiratorydysfunctioninchildrenandadolescentswithmucopolysaccharidosistypesiiiivaandvi